69340-07-4 Usage
Uses
Used in Cancer Research:
1,4-Dinitrosopiperazine-d8 is used as a research tool for studying the molecular mechanisms underlying the development and progression of nasopharyngeal carcinoma (NPC). Its organ specificity to the nasopharyngeal epithelium makes it a valuable compound for investigating the unique characteristics of this type of cancer.
Used in Drug Development:
1,4-Dinitrosopiperazine-d8 can be employed as a starting point for the development of potential therapeutic agents targeting nasopharyngeal carcinoma. By understanding the interactions of DNP-d8 with biological systems, researchers can design and synthesize new compounds with improved efficacy and selectivity for NPC treatment.
Used in Analytical Chemistry:
1,4-Dinitrosopiperazine-d8 is used as a labeled internal standard in mass spectrometry and other analytical techniques. The presence of deuterium atoms in DNP-d8 provides a distinct mass signature, allowing for accurate quantification and identification of related compounds in complex biological samples.
Used in Toxicology Studies:
1,4-Dinitrosopiperazine-d8 can be utilized in toxicological research to investigate the toxic effects of DNP and its metabolites on various organs and tissues. This information can be crucial for assessing the safety and potential side effects of DNP exposure in humans and animals.
Check Digit Verification of cas no
The CAS Registry Mumber 69340-07-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,9,3,4 and 0 respectively; the second part has 2 digits, 0 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 69340-07:
(7*6)+(6*9)+(5*3)+(4*4)+(3*0)+(2*0)+(1*7)=134
134 % 10 = 4
So 69340-07-4 is a valid CAS Registry Number.
69340-07-4Relevant academic research and scientific papers
Method for preparing deuterated amine compound by using microwave reaction device
-
Paragraph 0066-0070, (2019/05/28)
The invention provides a method for preparing a deuterated amine compound. The method comprises the step of converting a non-deuterated amine compound containing at least one structure of formula C-N-X into the deuterated amine compound by using a microwa
Deuterium-modified Abemaciclib derivative
-
Paragraph 0224; 0225; 0226; 0227; 0228, (2017/08/02)
The invention belongs to the field of medicinal chemistry and specifically relates to a deuterium-modified Abemaciclib derivative, a preparation method of the derivative, a pharmaceutical composition containing the deuterium-modified Abemaciclib derivative, and application of the deuterium-modified Abemaciclib derivative and the pharmaceutical composition in the preparation of a medicine for treating cell proliferative diseases. In comparison with Abemaciclib, some compounds of the invention (especially compounds in the embodiment) have more excellent pharmacokinetic properties. It is expected that clinical dosage will be reduced. Thus, treatment cost is reduced so as to benefit more patients.
Deuterated diphenylaminopyrimidine compound
-
Paragraph 0109; 0115; 0116; 0116; 0117; 0118, (2017/05/10)
The invention belongs to the field of medicine, and relates to a deuterated diphenylaminopyrimidine compound or a pharmaceutically acceptable salt thereof, and more particularly to a compound of the formula (I) or a pharmaceutically acceptable salt thereof, a preparation process thereof, a pharmaceutical composition thereof and application thereof in the treatment of a cell proliferative disease.
